MedTrace Logo

Heterologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine in Children 12-17 Years of Age

NCT05727215 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2025-06-03

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate immune response and safety of SARS-CoV-2 subunit protein recombinant vaccine (IndoVac) as a heterologous booster dose in healthy children 12-17 years of age.

Participants who had received complete primary doses of inactivated (Sinovac®) COVID-19 Vaccine will be given IndoVac as a booster dose.

Conditions

Interventions

BIOLOGICAL

SARS-CoV-2 subunit protein recombinant vaccine

SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma

Sponsors & Collaborators

  • Universitas Padjadjaran

    collaborator OTHER

  • PT Bio Farma

    lead INDUSTRY

Principal Investigators

  • Eddy Fadlyana, MD · Universitas Padjadjaran

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-02-28
Primary Completion
2024-02-22
Completion
2024-03-18

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05727215 on ClinicalTrials.gov